1. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
2. Novartis AG, Novartis’ new heart failure medicine LCZ696, now called Entresto, approved by FDA to reduce risk of cardiovascular death and heat failure hospitalization,https://www.novartis.com/news/media-releases/novartis-new-heart-failure-medicine-lcz696-now-called-entrestotm-approved-fda(accessed Jul 29, 2015) .
3. Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure
4. Dicarboxylic Acid Dipeptide Neutral Endopeptidase Inhibitors
5. Hook, D.; Riss, B.; Kaufmann, D.; Napp, M.; Bappert, E.; Polleux, P.; Medlock, J.; Zanotti-Gerosa, A.Process and intermediates for the preparation of 5-biphenyl-4-yl-2-methylpetanoic acid derivatives. World Patent, 2009,090,251 A2, Jul 23, 2009.